INTRODUCTION: Overweight women diagnosed with breast cancer have greater recurrence and mortality risks. Recent studies in advanced cancer showed that the combination of sarcopenia and an overweight or obese body mass index (BMI) is associated with poor clinical outcomes. OBJECTIVES: To compare pathological complete response (pCR) cases with controls and evaluate associations among a pCR, survival outcome, and sarcopenia as well as the combination of both sarcopenia and a BMI ≥25 kg/m(2). METHODS: Sixty-seven breast cancer patients with a pCR to neoadjuvant chemotherapy (NC) were matched with controls who did not have a pCR to NC. Patients were matched by age, Black's nuclear grading system, clinical cancer stage, and estrogen receptor and progesterone receptor status. Body composition was analyzed using computed tomography images taken prior to NC. RESULTS: BMI was associated with pCR. Among normal weight patients, the pCR rate was higher in sarcopenic patients and the progression-free survival (PFS) interval was significantly longer than in overweight or obese BMI patients. The death hazard was 2% higher for each unit higher skeletal muscle index and 0.6% higher for each unit higher visceral adipose tissue. CONCLUSIONS: Overweight patients treated with NC had a lower pCR rate and shorter PFS time. Among patients with a normal BMI, the pCR rate was better in sarcopenic patients. More research is required to evaluate the negative impact of sarcopenic obesity on prognosis and the contributors to better response rates in operable, normal weight breast cancer patients with sarcopenia.
INTRODUCTION: Overweight women diagnosed with breast cancer have greater recurrence and mortality risks. Recent studies in advanced cancer showed that the combination of sarcopenia and an overweight or obese body mass index (BMI) is associated with poor clinical outcomes. OBJECTIVES: To compare pathological complete response (pCR) cases with controls and evaluate associations among a pCR, survival outcome, and sarcopenia as well as the combination of both sarcopenia and a BMI ≥25 kg/m(2). METHODS: Sixty-seven breast cancerpatients with a pCR to neoadjuvant chemotherapy (NC) were matched with controls who did not have a pCR to NC. Patients were matched by age, Black's nuclear grading system, clinical cancer stage, and estrogen receptor and progesterone receptor status. Body composition was analyzed using computed tomography images taken prior to NC. RESULTS: BMI was associated with pCR. Among normal weight patients, the pCR rate was higher in sarcopenic patients and the progression-free survival (PFS) interval was significantly longer than in overweight or obese BMI patients. The death hazard was 2% higher for each unit higher skeletal muscle index and 0.6% higher for each unit higher visceral adipose tissue. CONCLUSIONS: Overweight patients treated with NC had a lower pCR rate and shorter PFS time. Among patients with a normal BMI, the pCR rate was better in sarcopenic patients. More research is required to evaluate the negative impact of sarcopenic obesity on prognosis and the contributors to better response rates in operable, normal weight breast cancerpatients with sarcopenia.
Authors: Bryan T Hennessy; Gabriel N Hortobagyi; Roman Rouzier; Henry Kuerer; Nour Sneige; Aman U Buzdar; Shu Wan Kau; Bruno Fornage; Aysegul Sahin; Kristine Broglio; S Eva Singletary; Vicente Valero Journal: J Clin Oncol Date: 2005-12-20 Impact factor: 44.544
Authors: R N Baumgartner; K M Koehler; D Gallagher; L Romero; S B Heymsfield; R R Ross; P J Garry; R D Lindeman Journal: Am J Epidemiol Date: 1998-04-15 Impact factor: 4.897
Authors: Nathan A Stephens; Calum Gray; Alisdair J MacDonald; Benjamin H Tan; Iain J Gallagher; Richard J E Skipworth; James A Ross; Kenneth C H Fearon; Carolyn A Greig Journal: Clin Nutr Date: 2012-01-31 Impact factor: 7.324
Authors: W D Dewys; C Begg; P T Lavin; P R Band; J M Bennett; J R Bertino; M H Cohen; H O Douglass; P F Engstrom; E Z Ezdinli; J Horton; G J Johnson; C G Moertel; M M Oken; C Perlia; C Rosenbaum; M N Silverstein; R T Skeel; R W Sponzo; D C Tormey Journal: Am J Med Date: 1980-10 Impact factor: 4.965
Authors: Rachna Raman; Sarah L Mott; Mary C Schroeder; Sneha Phadke; Jad El Masri; Alexandra Thomas Journal: Clin Breast Cancer Date: 2016-06-23 Impact factor: 3.225
Authors: Bette J Caan; Elizabeth M Cespedes Feliciano; Carla M Prado; Stacey Alexeeff; Candyce H Kroenke; Patrick Bradshaw; Charles P Quesenberry; Erin K Weltzien; Adrienne L Castillo; Taiwo A Olobatuyi; Wendy Y Chen Journal: JAMA Oncol Date: 2018-06-01 Impact factor: 31.777
Authors: Katelin A Mirkin; Franklyn E Luke; Alexandra Gangi; Jose M Pimiento; Daniel Jeong; Christopher S Hollenbeak; Joyce Wong Journal: J Gastrointest Oncol Date: 2017-06
Authors: Lisly Chéry; Leonardo D Borregales; Bryan Fellman; Diana L Urbauer; Naveen Garg; Nathan Parker; Matthew H G Katz; Christopher G Wood; Jose A Karam Journal: Urology Date: 2017-07-10 Impact factor: 2.649
Authors: Gianluca Ferini; Alberto Cacciola; Silvana Parisi; Sara Lillo; Laura Molino; Consuelo Tamburella; Valerio Davi; Ilenia Napoli; Angelo Platania; Nicola Settineri; Giuseppe Iati; Antonio Pontoriero; Stefano Pergolizzi; Anna Santacaterina Journal: In Vivo Date: 2021 Jan-Feb Impact factor: 2.155
Authors: Haiyun Wang; Shijia Zhang; Douglas Yee; Saonli Basu; Heather Beckwith; David Potter; Anne Blaes Journal: Breast Cancer Date: 2021-01-02 Impact factor: 4.239
Authors: Oluwadamilola M Fayanju; Carolyn S Hall; Jessica Bowman Bauldry; Mandar Karhade; Lily M Valad; Henry M Kuerer; Sarah M DeSnyder; Carlos H Barcenas; Anthony Lucci Journal: Am J Surg Date: 2017-06-23 Impact factor: 2.565
Authors: Ye Won Jeon; Hyung Soon Park; Yousun Ko; Yu Sub Sung; Byoung Yong Shim; Young Jin Suh; Hyun A Kim Journal: Breast Cancer Res Treat Date: 2021-07-20 Impact factor: 4.872